{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T13:25:57Z","timestamp":1793453157939,"version":"4.5.0"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T00:00:00Z","timestamp":1747699200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Remarkable clinical benefits have been achieved for patients with haemophilia through intravenously administered adeno-associated virus (AAV)-based liver-directed gene therapy. However, no comprehensive meta-analysis based on hemophilia types, various transgene types, AAV capsid, neutralizing antibody titers, and baseline factor VIII activity has been conducted to assess the efficacy of AAV vector gene therapy in hemophilic patients. We aimed to perform a systematic review and meta-analysis of the literature to assess the efficacy and safety of AAV-based gene therapy for hemophilia.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We systematically searched PubMed, Clinical Trials, Medline, Web of Science, Embase, Cochrane Central Register of Controlled Trials, and Cochrane Database of Systematic Reviews for clinical trials involving patients diagnosed with hemophilia and treated with AAV gene therapy. The outcomes included annualized bleeding rate (ABR), annualized infusion rate (AIR), the incidence of treatment-related adverse events (TRAEs), alanine aminotransferase (ALT) elevation, and aspartate transaminase (AST) elevation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 13 articles were selected from 879 articles for meta-analysis. Pooled analyses showed that after gene therapy, the ABR was 1.10 and the AIR was 3.92, respectively. At 1 year after AAV gene therapy, all participants exhibited factor activity levels above their baseline values, with the highest level reaching 93.47%. Additionally, 50% of the hemophilia patients had elevated TRAEs, 50% had elevated ALT levels, and 29% had elevated AST levels. We also performed a subgroup analysis of these results according to different haemophilia types, various transgene types, AAV capsids, neutralizing antibody titers, and baseline factor VIII activity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>Our analysis supported the efficacy and safety of AAV-mediated gene therapy for hemophilia, providing a reference for clinical practice and the development of more gene therapy drugs.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2025.1580264","type":"journal-article","created":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T09:58:23Z","timestamp":1747735103000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Adeno-associated virus gene therapy for hemophilia: an update meta-analysis and systematic review"],"prefix":"10.3389","volume":"12","author":[{"given":"Wuxia","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aidi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baoshan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,20]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41572-021-00278-x","article-title":"Haemophilia","volume":"7","author":"Berntorp","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1055\/s-0041-1723769","article-title":"Heterogeneity in bleeding tendency and Arthropathy development in individuals with hemophilia","volume":"47","author":"Rehill","year":"2021","journal-title":"Semin Thromb Hemost"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ajem.2022.02.045","article-title":"High risk and low prevalence diseases: hemophilia emergencies","volume":"56","author":"Alblaihed","year":"2022","journal-title":"Am J Emerg Med"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH guidelines for the Management of Hemophilia, 3rd edition[published correction appears in Haemophilia. (2021) 27(4):699. doi: 10.1111\/hae.14308]","volume":"26","author":"Srivastava","year":"2020","journal-title":"Haemophilia"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1177\/15353702221147565","article-title":"Gene therapy for hemophilia: looking beyond factor expression","volume":"247","author":"Yamaguti-Hayakawa","year":"2022","journal-title":"Exp Biol Med (Maywood)"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"e29305","DOI":"10.1002\/jmv.29305","article-title":"Infusion reactions to adeno-associated virus (AAV)-based gene therapy: mechanisms, diagnostics, treatment and review of the literature","volume":"95","author":"Notarte","year":"2023","journal-title":"J Med Virol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1046\/j.1445-2197.2003.02748.x","article-title":"Methodological index for non-randomized studies (minors): development and validation of a new instrument","volume":"73","author":"Slim","year":"2003","journal-title":"ANZ J Surg"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1136\/jech-2013-203104","article-title":"Meta-analysis of prevalence","volume":"67","author":"Barendregt","year":"2013","journal-title":"J Epidemiol Community Health"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.7326\/M22-0092","article-title":"Accuracy and efficiency of machine learning-assisted risk-of-Bias assessments in \"real-world\" systematic reviews: a noninferiority randomized controlled trial","volume":"175","author":"Arno","year":"2022","journal-title":"Ann Intern Med"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1136\/bmjebm-2017-110853","article-title":"Methodological quality and synthesis of case series and case reports","volume":"23","author":"Murad","year":"2018","journal-title":"BMJ Evid Based Med"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1056\/NEJMoa1708483","article-title":"AAV5-factor VIII gene transfer in severe hemophilia a","volume":"377","author":"Rangarajan","year":"2017","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1056\/NEJMoa1908490","article-title":"Multiyear follow-up of AAV5-hFVIII-SQ gene therapy for hemophilia a","volume":"382","author":"Pasi","year":"2020","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1056\/NEJMoa2113708","article-title":"Valoctocogene Roxaparvovec gene therapy for hemophilia a","volume":"386","author":"Ozelo","year":"2022","journal-title":"N Engl J Med"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1056\/NEJMoa2211075","article-title":"Two-year outcomes of Valoctocogene Roxaparvovec therapy for hemophilia a","volume":"388","author":"Mahlangu","year":"2023","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1056\/NEJMoa2104205","article-title":"Multiyear factor VIII expression after AAV gene transfer for hemophilia a","volume":"385","author":"George","year":"2021","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1182\/blood.2022018971","article-title":"Giroctocogene fitelparvovec gene therapy for severe hemophilia a: 104-week analysis of the phase 1\/2 Alta study","volume":"143","author":"Leavitt","year":"2024","journal-title":"Blood"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1182\/blood-2023-179422","article-title":"Four-year follow-up of the Alta study, a phase 1\/2 study of Giroctocogene Fitelparvovec (PF-07055480\/SB-525) gene therapy in adults with severe hemophilia A","volume":"142","author":"Harrington","year":"2023","journal-title":"Blood"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1056\/NEJMoa1407309","article-title":"Long-term safety and efficacy of factor IX gene therapy in hemophilia B","volume":"371","author":"Nathwani","year":"2014","journal-title":"N Engl J Med"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1056\/NEJMoa2119913","article-title":"Phase 1-2 trial of AAVS3 gene therapy in patients with hemophilia B","volume":"387","author":"Chowdary","year":"2022","journal-title":"N Engl J Med"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1056\/NEJMoa1708538","article-title":"Hemophilia B gene therapy with a High-specific-activity factor IX variant","volume":"377","author":"George","year":"2017","journal-title":"N Engl J Med"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1182\/blood-2017-09-804419","article-title":"Gene therapy with adeno-associated virus vector 5-human factor IX in adults with hemophilia B","volume":"131","author":"Miesbach","year":"2018","journal-title":"Blood"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"e504","DOI":"10.1016\/S2352-3026(22)00113-2","article-title":"Safety and activity of an engineered, liver-tropic adeno-associated virus vector expressing a hyperactive Padua factor IX administered with prophylactic glucocorticoids in patients with haemophilia B: a single-Centre, single-arm, phase 1, pilot trial","volume":"9","author":"Xue","year":"2022","journal-title":"Lancet Haematol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1056\/NEJMoa2211644","article-title":"Gene therapy with Etranacogene Dezaparvovec for hemophilia B","volume":"388","author":"Pipe","year":"2023","journal-title":"N Engl J Med"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1055\/s-0042-1758870","article-title":"Factor VIII and factor IX activity measurements for hemophilia diagnosis and related treatments","volume":"49","author":"Bowyer","year":"2023","journal-title":"Semin Thromb Hemost"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1056\/NEJMoa067659","article-title":"Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia","volume":"357","author":"Manco-Johnson","year":"2007","journal-title":"N Engl J Med"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1182\/blood-2018-08-872291","article-title":"New therapies for hemophilia","volume":"133","author":"Weyand","year":"2019","journal-title":"Blood"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1182\/hematology.2022000388","article-title":"Gene therapy for hemophilia","volume":"2022","author":"Nathwani","year":"2022","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"7736","DOI":"10.3390\/ijms24097736","article-title":"Viral vector-based gene therapy","volume":"24","author":"Li","year":"2023","journal-title":"Int J Mol Sci"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1182\/blood.2019003777","article-title":"Gene therapy for hemophilia: a review on clinical benefit, limitations, and remaining issues","volume":"138","author":"Leebeek","year":"2021","journal-title":"Blood"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1146\/annurev-med-043021-033013","article-title":"Adeno-associated virus gene therapy for hemophilia","volume":"74","author":"Samelson-Jones","year":"2023","journal-title":"Annu Rev Med"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1089\/hum.2023.208","article-title":"Efficacy and safety of adeno-associated virus-based clinical gene therapy for hemophilia: a systematic review and Meta-analysis","volume":"35","author":"Han","year":"2024","journal-title":"Hum Gene Ther"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"2524","DOI":"10.1182\/blood.2020005683","article-title":"Activity of transgene-produced B-domain-deleted factor VIII in human plasma following AAV5 gene therapy","volume":"136","author":"Rosen","year":"2020","journal-title":"Blood"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1373\/clinchem.2017.284356","article-title":"Advances in the treatment of hemophilia: implications for laboratory testing","volume":"65","author":"Tripodi","year":"2019","journal-title":"Clin Chem"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.3390\/jcm10112471","article-title":"Emerging immunogenicity and Genotoxicity considerations of adeno-associated virus vector gene therapy for hemophilia","volume":"10","author":"Monahan","year":"2021","journal-title":"J Clin Med"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1002\/hep.24625","article-title":"Toll-like receptor 2-mediated innate immune response in human nonparenchymal liver cells toward adeno-associated viral vectors","volume":"55","author":"H\u00f6sel","year":"2012","journal-title":"Hepatology"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1580264\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T09:58:25Z","timestamp":1747735105000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1580264\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,20]]},"references-count":35,"alternative-id":["10.3389\/fmed.2025.1580264"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1580264","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,20]]},"article-number":"1580264"}}